"Neoplasm Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
| Descriptor ID |
D009363
|
| MeSH Number(s) |
D12.776.624
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Proteins".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Proteins".
This graph shows the total number of publications written about "Neoplasm Proteins" by people in this website by year, and whether "Neoplasm Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 6 | 3 | 9 |
| 1997 | 3 | 3 | 6 |
| 1998 | 3 | 1 | 4 |
| 1999 | 5 | 3 | 8 |
| 2000 | 8 | 12 | 20 |
| 2001 | 8 | 3 | 11 |
| 2002 | 12 | 6 | 18 |
| 2003 | 17 | 4 | 21 |
| 2004 | 11 | 8 | 19 |
| 2005 | 8 | 5 | 13 |
| 2006 | 9 | 10 | 19 |
| 2007 | 7 | 8 | 15 |
| 2008 | 12 | 4 | 16 |
| 2009 | 6 | 7 | 13 |
| 2010 | 5 | 7 | 12 |
| 2011 | 10 | 6 | 16 |
| 2012 | 12 | 10 | 22 |
| 2013 | 11 | 7 | 18 |
| 2014 | 9 | 6 | 15 |
| 2015 | 8 | 10 | 18 |
| 2016 | 11 | 3 | 14 |
| 2017 | 4 | 3 | 7 |
| 2018 | 8 | 6 | 14 |
| 2019 | 11 | 8 | 19 |
| 2020 | 11 | 5 | 16 |
| 2021 | 8 | 3 | 11 |
| 2022 | 2 | 5 | 7 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 2 | 2 |
| 2025 | 2 | 0 | 2 |
| 2026 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Proteins" by people in Profiles.
-
Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies. J Immunother Cancer. 2026 Jul 20; 14(7).
-
Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models. J Clin Invest. 2026 May 15; 136(10).
-
STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model. J Clin Invest. 2026 Feb 16; 136(4).
-
Targeting legumain-mediated cell-cell interaction sensitizes glioblastoma to immunotherapy in preclinical models. J Clin Invest. 2025 May 15; 135(10).
-
RACK1 MARylation regulates translation and stress granules in ovarian cancer cells. J Cell Biol. 2025 Feb 03; 224(2).
-
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 12 30; 15(1):10743.
-
NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer. Mol Cancer. 2024 09 06; 23(1):188.
-
HIF-2a expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma. J Clin Invest. 2024 06 17; 134(12).
-
Anoctamin-1 is induced by TGF-ß and contributes to lung myofibroblast differentiation. Am J Physiol Lung Cell Mol Physiol. 2024 01 01; 326(1):L111-L123.
-
Poly(ADP-ribose) polymerase 9 mediates early protection against Mycobacterium tuberculosis infection by regulating type I IFN production. J Clin Invest. 2023 06 15; 133(12).